A
ADXS
vs
S&P 500
S&P 500
Over the past 12 months, ADXS has significantly outperformed S&P 500, delivering a return of +1 912% compared to the S&P 500's +13% growth.
Stocks Performance
ADXS vs S&P 500
Performance Gap
ADXS vs S&P 500
Performance By Year
ADXS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Advaxis Inc
Glance View
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.
